Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1203 • ACR Convergence 2020
Analysis of the Impact of Tofacitinib Treatment on Weight in Patients with Rheumatoid Arthritis
Jürgen Wollenhaupt¹, Jacques Morel², Claire Daien³, Adeline Ruyssen-Witrand⁴, Cédric Lukas³, Christophe Richez⁵, Andrea Shapiro⁶, Douglass S Chapman⁷, Magali Cros⁸, Jose L Rivas⁹ and Gustavo Citera¹⁰, ¹Struenseehaus Centre for Rheumatology and Clinical Immunology, Hamburg, Germany, ²Rheumatology department, CHU Montpellier and University of Montpellier, Montpellier, France, ³CHU Montpellier and University of Montpellier, Montpellier, France, ⁴Hôpital Purpan, CHU Toulouse, Toulouse, France, ⁵Groupe Hospitalier Pellegrin-CHU de Bordeaux, Bordeaux, France, ⁶Pfizer Inc, Peapack, NJ, ⁷Pfizer Inc, New York, NY, ⁸Pfizer Inc, Paris, France, ⁹Pfizer SLU, Madrid, Spain, ¹⁰Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina
Background/Purpose: A prior post hoc analysis of tofacitinib clinical trial data reported improvements in RA outcomes with tofacitinib vs placebo (PBO) through Month (M)6, regardless…
Abstract Number: 1219 • ACR Convergence 2020
Reaching Remission by IL-1 Inhibition in Rheumatoid Arthritis Patients with Type 2 Diabetes Improves the Glucose Homeostasis: Long-term Findings from TRACK Study, a Multicentre, Open-label, Randomised, Controlled Trial
Piero Ruscitti¹, Onorina Berardicurti¹, Paola Cipriani¹ and Roberto Giacomelli¹, ¹University of L'Aquila, L'Aquila, Italy
Background/Purpose: The inflammatory contribution to type 2 diabetes (T2D) has suggested new therapeutic targets by using biologic DMARDs designed for rheumatoid arthritis (RA), and IL-1…
Abstract Number: 1237 • ACR Convergence 2020
Pain and Other Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Who Did or Did Not Achieve Treatment Response Based on Improvement in Swollen Joints in Tocilizumab Clinical Trials
Anthony Sebba¹, Jian Han² and Shalini V. Mohan², ¹Arthritis Associates, Palm Harbor, Tampa, FL, ²Genentech, South San Francisco, CA
Background/Purpose: Recent data suggest that rheumatoid arthritis (RA) pain may be noninflammatory and inflammatory, and improvement in pain scores and other patient-reported outcomes (PROs) may…
Abstract Number: 1462 • ACR Convergence 2020
Intensity and Duration of Silica Exposure Increase Rheumatoid Arthritis Risk Among Coal Miners
Laura Trupin¹, Gabriela Schmajuk², Edward Yelin¹ and Paul Blanc¹, ¹UCSF, San Francisco, CA, ²University of California, San Francisco, Atherton, CA
Background/Purpose: Exposure to inhaled mineral dust, particularly silica, has been associated with increased risk of rheumatoid arthritis and other autoimmune diseases. Coal mining, which can…
Abstract Number: 1537 • ACR Convergence 2020
Usefulness of Ultrasound Assessment of Sarcopenia in Patients with Rheumatoid Arthritis
Takeshi Yoshida¹ and Yoshitaka Kumon¹, ¹Chikamori Hospital, Kochi, Japan
Background/Purpose: Sarcopenia, the age-related loss of muscle mass and function, is associated with numerous risk factors, including rheumatoid arthritis (RA). Although standard diagnostic tool for…
Abstract Number: 1600 • ACR Convergence 2020
Relationship Between Electronic Health Record Vendor and Performance on Patient-reported Outcome Quality Measures in the ACR’s Rheumatology Informatics System for Effectiveness (RISE) Registry
Nevin Hammam¹, Gabriela Schmajuk², Jing Li³, Michael Evans¹, Julia Kay¹ and Jinoos Yazdany³, ¹UCSF, San Francisco, CA, ²University of California, San Francisco, Atherton, CA, ³University of California, San Francisco, San Francisco, CA
Background/Purpose: Routine collection of disease activity and patient reported outcomes (PROs) such as functional status assessment in rheumatoid arthritis (RA) are nationally endorsed quality measures…
Abstract Number: 1722 • ACR Convergence 2020
Predicting Rheumatoid Arthritis Using the Symptoms in Persons at Risk of Rheumatoid Arthritis (SPARRA) Questionnaire
Laurette van Boheemen¹, Marieke ter Wee², Marie Falahee³, Marian van Beers⁴, Axel Finckh⁵, Aase Hensvold⁶, Karim Raza⁷ and Dirkjan van Schaardenburg⁸, ¹Amsterdam Rheumatology and immunology Center | Reade, Amste, Netherlands, ²Amsterdam Rheumatology and Immunology Center, location Amsterdam UMC, VUmc, Amsterdam, Netherlands, ³Sandwell and West Birmingham Hospitals NHS Trust, Birminham, United Kingdom, ⁴Amsterdam Rheumatology and immunology Center | Reade, Amsterdam, Netherlands, ⁵Division of Rheumatology, University Hospitals of Geneva, Geneva, Switzerland, ⁶Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, ⁷Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom, ⁸Amsterdam Rheumatology and immunology Center | Reade and Amsterdam UMC, Amsterdam, Netherlands
Background/Purpose: Accurate prediction of rheumatoid arthritis (RA) development in persons at risk can help to select individuals for early intervention trials. At-risk individuals exhibit a…
Abstract Number: 1738 • ACR Convergence 2020
Promote Treat-to-Target for RA via Empowering Patients: A Cohort Study from China by Smart System of Disease Management (SSDM)
Jing Yang¹, Rong Mu², Chun Li³, Bin Wu⁴, Hongzhi Wang⁵, Wenqiang Fan⁶, Jinmei Zou⁷, Yu Zhang¹, Fen Li⁸, Xiaofeng Rong⁹, Jianhong Wu¹⁰, Yong Wang¹¹, Shengguang Li¹², Yi Zhao¹³, Xiaoqiang Hou¹⁴, Hui Xiao¹⁵, Yuhua Jia¹⁶, Bing Wu¹⁶, Miaomiao Song¹⁶, Fei Xiao¹⁶ and Zhanguo Li¹⁷, ¹Department of Rheumatology, Mianyang Central Hospital, Mianyang, China (People's Republic), ²People's Hospital, Beijing University Medical School, Beijing, Beijing, China (People's Republic), ³People's Hospital, Beijing University Medical School, beijing, China (People's Republic), ⁴Chongqing Hospital of Traditional Chinese Medicine, chongqing, China (People's Republic), ⁵The First Hospital of Jiaxing, Jiaxing, China (People's Republic), ⁶Central Hospital of XinXiang, Xinxiang, China (People's Republic), ⁷Department of Rheumatology, Mianyang Central Hospital, Mianyang, Sichuan, China (People's Republic), ⁸The Second Xiangya Hospital of Central South University, hunan, China (People's Republic), ⁹The First Affiliated Hospital of Chongqing Medical University, chongqing, China (People's Republic), ¹⁰Department of Rheumatology, Dazhou Central Hospital, Dazhou, China (People's Republic), ¹¹The first Hospital Affiliated to AMU (Southernwest Hospital), chongqing, China (People's Republic), ¹²Peking University International Hospital, Beijing, China (People's Republic), ¹³Xuanwu Hospital, Capital Medical University, Beijing, China, Beijing, China (People's Republic), ¹⁴Yichang Central People's Hospital, Beijing, China (People's Republic), ¹⁵Shanghai Gothic Internet Technology Co., Ltd., Shanghai, Shanghai, China (People's Republic), ¹⁶Shanghai Gothic Internet Technology Co., Ltd., Shanghai, China (People's Republic), ¹⁷Peking University People’s Hospital, Xicheng, Beijing, China (People's Republic)
Background/Purpose: Treat-to-Target (T2T) strategy are critical for the treatment of RA, but Chinese rheumatologists can hardly provide patients with a complete assessment in the clinic…
Abstract Number: 1756 • ACR Convergence 2020
Comparable Long-Term Outcomes Among DAS28-ESR-based Remission Criteria and ACR/EULAR Definitions in Patients with Established Rheumatoid Arthritis
Felipe Julio Ramirez Garcia¹, Jose Inciarte-Mundo², Andrea Cuervo³, Raquel Celis⁴, Virginia Ruiz-Esquide⁴, Raul Castellanos-Moreira⁵, Andres Ponce⁴, Jose Gómez-Puerta⁶, Raimon Sanmartí⁶ and Juan Cañete⁷, ¹Arthritis Unit, Rheumatology Dpt, Hospital Clinic, Barcelona, Spain, Barcelona, Catalonia, Spain, ²Hospital Universitari Clínic de Barcelona, Barcelona, ³Hospital Clínic, Barcelona, Spain, ⁴Hospital Clinic, Barcelona, Spain, ⁵Hospital Clinic of Barcelona, Barcelona, Spain, ⁶Hospital Universitari Clínic de Barcelona, Barcelona, Catalonia, Spain, ⁷Arthritis Unit, Rheumatology Dpt, Hospital Clinic, Barcelona, Spain and IDIBAPS, Barcelona, Spain
Background/Purpose: To compare long-term clinical and radiographic outcomes among five sets of remission criteria [four clinical and one Ultrasound (US)-based] in a cohort of RA…
Abstract Number: 1897 • ACR Convergence 2020
Trends in Hospitalizations for Vertebral Compression Fractures in Ankylosing Spondylitis: Data from the National Inpatient Sample 2001-2014
Anish Paudel¹, Rashmi Dhital², Dilli Poudel³, Anthony Donato¹ and Paras Karmacharya⁴, ¹Reading Hospital and Medical Center, West Reading, PA, ²Reading Hospital and Medical Center, West Reading, ³University of Pennsylvania, Philadelphia, PA, ⁴Mayo Clinic, Rochester MN, ROCHESTER, MN
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease predominantly affecting the spine, leading to syndesmophyte formation, ankylosis, and osteoporosis. These factors have been associated…
Abstract Number: 1998 • ACR Convergence 2020
Ten-year Analysis of the Risk of Severe Outcomes Related to Very Low-dose Glucocorticoids in Early Rheumatoid Arthritis
Camille Roubille¹, Amandine Coffy², Nathalie Rincheval², Jean Pierre Daures², René-Marc Flipo³, Maxime Dougados⁴ and Bernard Combe⁵, ¹CHU LAPEYRONIE, Montpellier, France, ²INSERM, Montpellier, France, ³Univ-Lille, CHU Lille, department of rheumatology, Lille, France, ⁴Department of Rheumatology, Hopital Cochin, Université de Paris, Paris, France, ⁵University of Montpellier, Montpellier, France
Background/Purpose: Although glucocorticoids (GC) remain an essential part of the therapeutic strategy in Rheumatoid Arthritis (RA), the long-term risk of adverse events of low-dose GC…
Abstract Number: 2045 • ACR Convergence 2020
Resident Memory T Cells in Synovial Tissue Mediate Arthritis Flares
Margaret Chang¹, Anais Levescot², Nathan Nelson-Maney², Rachel Blaustein², Kellen Winden¹, Allyn Morris³, Spoorthi Balu³, Alexandra Wactor², Ricardo Grieshaber-Bouyer⁴, Kevin Wei⁵, Lauren Henderson⁶, Rachael Clark³, Deepak Rao², Robert Fuhlbrigge⁷ and Peter Nigrovic⁸, ¹Boston Children's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, ⁴Department of Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany; Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA, Heidelberg, Germany, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Boston Children's Hospital, Watertown, MA, ⁷University of Colorado, Denver, CO, ⁸Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA, Boston
Background/Purpose: Resident memory T cells (TRM) are site-specific memory T cells that take up long-term residence in peripheral tissues and aid in local immune defense.…
Abstract Number: L11 • 2019 ACR/ARP Annual Meeting
Maintenance of Remission Following Dose De-Escalation of Abatacept in Early, MTX-Naïve, ACPA-Positive Patients with RA: Results from a Randomized Phase IIIb Study
Paul Emery¹, Yoshiya Tanaka ², Vivian Bykerk ³, Thomas W.J. Huizinga ⁴, Gustavo Citera ⁵, Clifton Bingham ⁶, Subhashis Banerjee ⁷, Benjamin Soule ⁸, Marleen Nys ⁹, Sean Connolly ¹⁰, Robert Wong ¹⁰, Kuan-Hsiang Gary Huang ⁷ and Roy Fleischmann ¹¹, ¹University of Leeds and Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Hospital for Special Surgery, New York City, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ⁶Johns Hopkins University, Baltimore, ⁷Bristol-Myers Squibb, Princeton, NJ, ⁸Bristol-Myers Squibb, Princeton, New Jersey, ⁹Bristol-Myers Squibb, Braine L'Alleud, Belgium, ¹⁰Bristol-Myers Squibb, Princeton, ¹¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Although EULAR/ACR guidelines suggest tapering biologics following sustained remission in patients (pts) with RA, specific de-escalation (DE) regimens are not fully defined. The Phase…
Abstract Number: 100 • 2019 ACR/ARP Annual Meeting
Targeting ITK Signaling Ameliorates Collagen-Induced Arthritis via Shifting the Balance Between Th17 and Regulatory Th17 Cells
Ye Chen¹, Julie Wang ², Nancy Olsen ³, Wael Jarjour ⁴ and Song Guo Zheng ⁴, ¹Ohio State University, Columbus, OH, ²Ohio State University, columbus, ³Penn State University, Hershey, PA, ⁴Ohio State College of Medicine, Columbus, OH
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease that cannot be cured and current approaches have some severe side effects. Although the pathogenesis is…
Abstract Number: 524 • 2019 ACR/ARP Annual Meeting
A Comparison of Upadacitinib Plus Methotrexate and Upadacitinib Plus Other CsDMARDs in Patients with Rheumatoid Arthritis: An Analysis of Two Phase 3 Studies
Joel Kremer¹, Filip Van den Bosch ², Andrea Rubbert-Roth ³, Sebastiao Radominski ⁴, Gerd Burmester ⁵, Heidi Camp ⁶, Sebastian Meerwein ⁷, Mark Howard ⁸, Yanna Song ⁹, Sheng Zhong ¹⁰ and Bernard Combe ¹¹, ¹Albany Medical College, Albany, NY, ²Ghent University Hospital, Ghent, Belgium, ³Kantonsspital St. Gallen, St Gallen, Switzerland, ⁴Universidade Federal do Paraná, Curitiba, Brazil, ⁵Charité—University Medicine Berlin, Berlin, Germany, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie GmbH Co. KG, Ludwigshafen, Germany, Wiesbaden, Germany, ⁸AbbVie Inc., North Chicago, ⁹AbbVie Inc., North Chicago, IL, USA, North Chicago, ¹⁰AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ¹¹CHU Montpellier, Montpellier University, Montpellier, France
Background/Purpose: Upadacitinib (UPA), a selective JAK1 inhibitor, has shown efficacy in patients with rheumatoid arthritis (RA) when combined with methotrexate (MTX) or other conventional synthetic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].